Skip to main content
. 2018 Nov 2;21(3):314–325. doi: 10.1093/neuonc/noy177

Table 1.

Demographics, tumor features, and clinical outcome of 19 study participants

Patient Age,y M:F Other Medical Conditions Size at Time of PET (cm 3) MDT Classification Tumor Side Cystic/Solid Tumor Clinical Outcome Histology (if known)
1 66.6 F HTN, T2DM, ocular melanoma (left eye), CKD stage 3 0.26 Shrinking R Solid Follow-up NA
2 32.3 M Nil 1.88 Growing L Solid Surgery Schwannoma, WHO grade I
3 25.7 M Nil 3.82 Growing R Small posteromedial cyst Surgery Schwannoma, WHO grade I
4 58.8 F T2DM, HTN 0.92 Static R Solid Follow-up NA
5 60.8 F Nil 1.03 Static R Solid Follow-up NA
6 56.3 F Depression 0.30 Static R Solid Surgery Schwannoma, WHO grade I
7 69.2 F OA, anxiety 0.59 Shrinking L Solid Follow-up NA
8 26.8 M Nil 1.92 Shrinking L Small cysts Follow-up NA
9 61.1 F Hashimoto’s, OA, hypothyroidism, Raynaud’s, pre-diabetes 0.37 Static R Solid Surgery Schwannoma, WHO grade I
10 76.1 F Nil 1.25 Static L Small anterolateral cyst Follow-up NA
11 74.9 M T2DM 1.09 Growing R Solid SRS NA
12 64.6 F Nil 0.97 Growing R Solid SRS NA
13 73.9 F Hypothyroidism 0.80 Static R Solid Follow-up NA
14 80.7 M BPH 0.99 Shrinking R Solid Follow-up NA
15 63.0 M Asthma 0.38 Static L Solid Surgery Schwannoma, WHO grade I
16 58.2 M HTN 0.73 Static R Solid Follow-up NA
17 54.3 M HTN 3.33 Growing L Solid Surgery Schwannoma, WHO grade I
18 54.8 F T2DM 5.71 Growing L Small multiple cysts Surgery Schwannoma, WHO grade I
19 39.0 F Nil 2.61 Growing R Small multiple cysts Surgery Schwannoma, WHO grade I

BPH = benign prostatic hypertrophy; CKD = chronic kidney disease; HTN = hypertension; NA = not applicable; OA = osteoarthritis; SRS = stereotactic radiosurgery; T2DM = type 2 diabetes.